Suppliers who imply human therapeutic effects are operating outside what the published research supports and in the UK, outside what the regulatory frame permits
Some patients experience fatigue followed by gradual improvement as their body responds to treatment
Oda Y, Tu C-L, Menendez A, Nguyen T, Bikle DD
Important Caveats About the Research Several important limitations should be acknowledged when reviewing the EpitalON literature: The majority of published studies originate from Khavinson's research group or closely affiliated laboratories Independent replication outside Russia has been limited, though the 2025 Biogerontology study represents a notable exception Human clinical data remains sparse, consisting mainly of small studies from one research group Most research has used injectable EpitalON, not oral formulations The peptide is not approved as a medicine in the UK, EU, or US How EpitalON Capsules Are Typically Taken Research Protocol Context The research literature commonly references cycles of 10-20 days at 5-10mg daily, repeated periodically (such as once or twice yearly)
Chronic alcohol consumption can weaken the immune system, making it harder for the body to fight off infections
Those patients should not experiment with immune-active compounds without medical review
